Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Daniel Horton¹, Charu Verma², Sanika Rege², Alicia Iizuka², Matthew Iozzio³, Dawn Koffman³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard², Lauren Parlett⁶, Carlos Rose⁷ and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ⁵New Jersey Medical School, Newark, NJ, ⁶Carelon Research, Inc, Wilmington, DE, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, New Brunswick
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
Abstract Number: 1989 • ACR Convergence 2025
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Victoria Koenigsberger¹, Madeleine Ward², Meghan Geary³ and Ali Yalcindag⁴, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²The Warren Alpert Medical School of Brown University, Division of Medicine-Pediatrics, Providence, ³The Warren Alpert Medical School of Brown University, Division of General Internal Medicine, Providence, ⁴The Warren Alpert Medical School of Brown University, Division of Rheumatology, Department of Pediatrics, Milton, MA
Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…
Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Neta Berlak¹, Lydia Christodoulou², Gil Amarilyo³, Oded Scheuerman⁴, Irit Tirosh⁵, Eyal Kristal⁶, Ester Forer⁷, Amit Carmi⁸, Alon Kalter⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israel, Tel Aviv, Israel, ²Tel Hashomer, Periatric rheumatology unit, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴schneider children's meidcal center of Israel, Petah tikva, Israel, ⁵Tel Aviv universty, Ramat Gan, Israel, ⁶Soroka medical center Beer Sheva, Beer Sheva, Israel, ⁷Soroka medical center, Beer Sheva, Israel, ⁸Schneider children's meidcal center of Israel, Tel Aviv, Israel, ⁹Schneider children's medical center of ISrael, Petah Tikva, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…
Abstract Number: 0418 • ACR Convergence 2025
Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
Patricia Vega-Fernandez¹, Kelly Rogers², Alyssa Sproles², Sherry Thornton¹, Lexi Auld³, Jackeline Rodriguez-Smith¹, Ekemini Ogbu¹, Kara Murphy Schmidt⁴, McKenzie Vater⁵, Katelyn Banschbach⁶, Grant Schulert¹, Alexei Grom¹, Sheila Angeles-Han², Hermine Brunner¹, Jennifer Huggins⁷, Daniel Lovell¹, Amy Cassedy⁸, Yuriy Baglaenko², Tracy Ting¹ and Sara Szabo¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Louisville, KY, ⁵Cincinnati Children's Hospital Medical Center, Fort Thomas, KY, ⁶cincinnati Children's hospital, Villa Hills, KY, ⁷Cincinnati Children's Medical Center, Cincinnati, OH, ⁸Cincinnati Children's hospital medical center, cincinnati, OH
Background/Purpose: Clinical, radiologic and biomarker data are measurements used in the assessment of juvenile idiopathic arthritis (JIA) disease activity. The development of ultrasound-guided synovial biopsy…
Abstract Number: 0399 • ACR Convergence 2025
External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Daniel Horton¹, Lauren Parlett², Yuyang Zhu³, Sanika Rege⁴, Patricia Hoffman⁵, Daniel Reiff⁶, Sarah McGuire⁷, Sonia Pothraj⁸, Cynthia Salvant⁹, Lakshmi Moorthy¹, Cecilia Huang⁴, Dawn Koffman⁴, Matthew Iozzio³, Alicia Iizuka⁴, Kevin Schott², Stephen Crystal¹⁰, Amy Davidow¹¹, Tobias Gerhard⁴, Kevin Haynes¹², Brian Strom¹³, Daniel Beachler² and Carlos Rose¹⁴, ¹Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon Research, Inc, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ⁵Hospital for Special Surgery, New York, NY, ⁶Boys Town National Research Hospital, Boys Town, ⁷Department of Obstetrics and Gynecology, Cooper Medical School, Camden, Camden, NJ, ⁸Washingtonville Pediatrics, Washingtonville, NY, ⁹Albany Medical Center, Albany, NY, ¹⁰Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ¹¹New Jersey Medical School, Newark, NJ, ¹²Janssen Research & Development, Titusville, NJ, ¹³Rutgers Biomedical and Health Sciences, New Brunswick, ¹⁴Thomas Jefferson University, Wilmington, DE
Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…
Abstract Number: 2680 • ACR Convergence 2025
High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Anna Costello¹, Rui Xiao¹, Jahan Jazayeri¹, Timothy Brandon¹, Xuemei Zhang¹, Irit Rasooly¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy and improves outcomes, yet JIA patients often experience circuitous pathways to diagnosis.…
Abstract Number: 1978 • ACR Convergence 2025
Utilizing a Gap to Target Function in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry Dashboard of Quality Measures
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Kerry Ferraro⁴, Erik Friedrichsen⁵, Cagri Yildirim-Toruner⁶, Ted Wimmel⁷, Delores Mincarelli⁸, Magen Phillips⁹ and Esi Morgan¹⁰, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children's Hospital, Hershey, PA, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁵Seattle Children's Hospital, Burien, WA, ⁶Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁷Hive Solutions, LLC, Cincinnati, OH, ⁸Hive Solutions, LLC, Newport, KY, ⁹Hive Solutions, LLC, Blue Ash, OH, ¹⁰Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning health network organized to improve outcomes of juvenile idiopathic arthritis (JIA).…
Abstract Number: 1280 • ACR Convergence 2025
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Yonatan Butbul Aviel¹, Arad Dotan², Dana Arnheim² and Cynthia Freiberg³, ¹Rambam Health Care Campus, Haifa, Israel, ²Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, Tel Aviv, Israel, ³Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv
Background/Purpose: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims…
Abstract Number: 0417 • ACR Convergence 2025
Implementation of a Communication Aid in Juvenile Idiopathic Arthritis Patient Visits, a Quality Improvement Study
Nazlican Civilibal Tang¹, Rachel Guess², Ran Hazan³, Amy Monahan⁴ and Maleewan Kitcharoensakkul⁵, ¹WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST.LOUIS, MISSOURI, St.Louis, MO, ²WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST.LOUIS, MISSOURI, st.louis, ³WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST.LOUIS, MISSOURI, Saint Louis, MO, ⁴WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST.LOUIS, MISSOURI, St. Louis, MO, ⁵Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a childhood onset autoimmune disease requiring long-term care and personalized treatment. Through a rigorous series of mixed patient and…
Abstract Number: 0398 • ACR Convergence 2025
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy² and Ginger Janow³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ³Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
Abstract Number: 2679 • ACR Convergence 2025
Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort
Vilde Øverlien Dåstøl¹, Ida Henriette Caspersen², Kristine Løkås Haftorn³, Sigrid Hestetun⁴, Siri Eldevik Håberg⁵, Karen H. Costenbader⁶, Marin Strøm⁷, Sjurdur Frodi Olsen⁸, Anne Lise Brantsæter⁹, Ketil Størdal¹⁰ and Helga Sanner¹, ¹Oslo University Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, ⁵Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, ⁶Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁷Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, ⁸Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, ⁹Norwegian Institute of Public Health, Department of Food Safety and Centre for Sustainable Diets, Oslo, Norway, ¹⁰Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway
Background/Purpose: Early-life nutrition may influence the risk of immune-mediated diseases like juvenile idiopathic arthritis (JIA). The benefits of breastfeeding are well established, but findings related…
Abstract Number: 1929 • ACR Convergence 2025
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
Michael Marrone¹, Christopher McPherson² and Abiola Oladapo³, ¹Sobi Inc., Mt Pleasant, SC, ²Sobi, University City, MO, ³Sobi INC, Waltham, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of rheumatologic disease. MAS is a form of secondary hemophagocytic lymphohistiocytosis which occurs most frequently…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 0416 • ACR Convergence 2025
Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
Narendra Bagri¹, Pavneet Kaur², Farheen KS², Bala Siva rama Krishna J², Banoth Sreesanth², Ayisha KP², Bareddy Sai Thrisha Reddy², ASHISH DATT UPADHYAY², RAKESH LODHA² and Sushil Kumar kabra², ¹All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: We aimed to study the outcomes (remission, flare, and adverse events) of biological disease-modifying anti-rheumatic drugs (bDMARD) in children with JIA from a low-middle-income…
Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Anna Sutton¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].